title: Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.
abstract: The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-CD30 monoclonal antibody cAC10. This ADC potently interferes with the growth of CD30-positive haematological tumours, including Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma. This study found improved antitumour activity in a preclinical model of HL when SGN-35 was combined with chemotherapeutic regimens such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or gemcitabine. Improved efficacy was also observed in high tumour burden models, indicating that combining ADCs with chemotherapeutic agents may be advantageous for the treatment of patients with relapsed or refractory HL.
authors.affiliation: Department of Preclinical Therapeutics, Seattle Genetics Inc., Bothell, WA 98021, USA.
authors.forename: Ezogelin
authors.initials: E
authors.lastname: Oflazoglu
authors.forename: Kim M
authors.initials: KM
authors.lastname: Kissler
authors.forename: Eric L
authors.initials: EL
authors.lastname: Sievers
authors.forename: Iqbal S
authors.initials: IS
authors.lastname: Grewal
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Gerber
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000628:therapy*; D018796:Immunoconjugates / Q000008:administration & dosage*; D017730:Ki-1 Antigen / Q000008:administration & dosage*; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009842:Oligopeptides / Q000008:administration & dosage*; D050257:Tubulin Modulators / Q000008:administration & dosage*; D014747:Vinblastine / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D009842:Oligopeptides; D050257:Tubulin Modulators; D003841:Deoxycytidine; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; C495575:monomethyl auristatin E; D000093542:Gemcitabine